Bayer AG's proposed $7.25 billion settlement of Roundup litigation ran into a new legal complication after the U.S. Judicial Panel for Multidistrict Litigation (JPML) granted a conditional transfer that could relocate the case into federal court and possibly fold it into the Roundup multidistrict litigation (MDL) already assigned to Judge Vince Chhabria in California. The market reaction was swift, with Bayer shares falling by more than 5%.
Analysts at Barclays said the JPML move adds layers of procedural uncertainty and increases the risk that the settlement's timeline will shift. They emphasized, however, that the transfer is conditional and does not by itself decide which forum has jurisdiction over the dispute.
Bayer maintains that removal to federal court is improper. Judge Chhabria has previously signaled he does not view himself as the right official to rule on the settlement framework, saying he would prefer the issue to be taken up by the appellate courts in Missouri and, potentially, the U.S. Supreme Court.
The settlement in question has already won preliminary approval in Missouri state court. Barclays noted that the agreement reflects substantial alignment between Bayer and a broad group of plaintiffs on both its structure and the economic terms agreed to by the parties.
Despite that alignment, Barclays pointed out a potential complication if the case is transferred to federal court: Judge Chhabria has publicly questioned whether a state-court approval can bind future claimants nationwide who were exposed to Roundup but have not developed cancer. That line of inquiry could present an obstacle to the settlement's nationwide effect if the federal venue asserts jurisdiction.
Barclays also stressed that the JPML action does not reopen the scientific questions surrounding glyphosate, does not expand Bayer's legal exposure, and does not change the settlement's negotiated structure. The analysts found no clear evidence that claimant behaviour has shifted in response to the jurisdictional dispute.
"The core mechanics remain intact," Barclays said, noting that the June 4 opt-out deadline for claimants remains in place. The brokerage expects Bayer to issue a statement in mid-June following its due diligence and said the principal uncertainty now is whether the July 9 fairness hearing could be postponed while the venue question is resolved. Any postponement, Barclays added, would likely be incremental.
Bayer characterized the most recent challenge as a "last-ditch" attempt to disrupt the settlement process, according to Barclays. The brokerage further indicated that the present dispute does not affect the substance of a separate U.S. Supreme Court matter related to glyphosate litigation that is expected to be decided in late June or early July.
Context for markets and stakeholders: The development touches legal, agricultural chemical, and broader equity markets. A delay or alteration in the settlement timeline could influence investor sentiment toward Bayer and market participants watching litigation-driven liabilities in the chemicals and crop science sectors.